Pfizer Reports Positive Results From LYRICA Study In Pediatric Epilepsy Patients

Shutterstock photo

( - Pfizer Inc. ( PFE ) reported positive top-line results of a study that evaluated the use of LYRICA (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to 16 years of age with partial onset seizures. The company said the results showed that adjunctive treatment with LYRICA 10 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint.

The LYRICA Pediatric Epilepsy Program is composed of a total of six studies in patients with epilepsy evaluating LYRICA as adjunctive therapy, three of which have been completed and three are actively enrolling.

In the U.S., LYRICA is indicated to treat fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles in adults. LYRICA is also indicated to treat partial onset seizures in adults with epilepsy who take one or more drugs for seizures.

This article appears in: Technology
Referenced Symbols: PFE

More from RTT News


See headlines for PFE

Follow on: